Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.
Volatility and Risk
Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Valuation and Earnings
This table compares Unicycive Therapeutics and Siga Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | N/A | N/A | -$26.56 million | ($1.75) | -2.87 |
| Siga Technologies | $53.66 million | 4.28 | $23.28 million | ($0.05) | -64.00 |
Siga Technologies has higher revenue and earnings than Unicycive Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for Unicycive Therapeutics and Siga Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
Unicycive Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 272.76%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Siga Technologies.
Profitability
This table compares Unicycive Therapeutics and Siga Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
| Siga Technologies | -5.19% | -1.55% | -1.32% |
Summary
Unicycive Therapeutics beats Siga Technologies on 7 of the 13 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
